Skip to main content
Clinical Trials/NCT00570440
NCT00570440CompletedPhase 4

Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills

FHI 3602 sites in 2 countries362 target enrollmentStarted: August 2007Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
FHI 360
Enrollment
362
Locations
2
Primary Endpoint
12 month cumulative COC discontinuation probabilities

Study Overview

Brief Summary

The primary objective is to determine if continuous COC use leads to higher continuation rates over 12 months of follow up than use of the standard 28-day COC regimen.

Detailed Description

Family Health International has recently initiated a USAID funded study to investigate the pregnancy rates, continuation rates, and acceptability of COCs in women taking COCs by the 21/7 cyclic regimen compared with the continuous use of COCs with bleeding-signaled hormone-free intervals. The primary objective is to determine whether continuous COC use leads to higher 12-month continuation rates than use of the standard 28-day COC regimen. Secondary objectives are to 1) compare pregnancy probabilities through 6 and 12 months between the continuous use group and the 28-day group 2) compare COC continuation rates through 6 months between the continuous use group and the 28-day group 3) compare acceptability of the two COC regimens 4) to compare bleeding and other side effects between the continuous use group and the 28-day group 5) to compare hemoglobin/hematocrit between the continuous use group and the 28-day group

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 30 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age 18-30
  • Currently has menstrual periods every 21-35 days
  • Willing and able to be randomly assigned to one of the two study groups and to comply with all study requirements
  • Has signed the informed consent form
  • Has a negative urine pregnancy test at enrollment

Exclusion Criteria

  • Has contraindications to COC use (see WHO MEC-3rd edition)
  • Is in any other research study
  • Has been pregnant in the past 3 months
  • Is breastfeeding or has breastfed in the past 3 months
  • Is currently using an IUD (women who agree to IUD removal are eligible once the IUD is removed)
  • Has had an injection of DMPA in the past 6 months
  • Has had an injection of NET-EN in the past 3 months
  • Has used combined injectables, oral contraceptive pills, implants, or a hormonal IUD in the past 2 months
  • Has had any of the following conditions since her last pregnancy, or since menarche if never pregnant:
  • Pelvic infection treated with antibiotics
  • Diagnosis of infertility
  • Endometriosis

Arms & Interventions

A

Experimental

Intervention: Oral contraceptives--ethinyl estradiol, levonorgestrel (Drug)

B

Active Comparator

Intervention: Oral contraceptives--ethinyl estradiol, levonorgestrel (Drug)

Outcomes

Primary Outcomes

12 month cumulative COC discontinuation probabilities

Time Frame: 12 months

Secondary Outcomes

  • Pregnancy rates through 6 and 12 months; 6 month cumulative discontinuation probabilities; acceptability; bleeding and other side effects; hemoglobin/hematocrit(12 months)

Investigators

Sponsor
FHI 360
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials